[arjie]

I told a friend of mine this and he pointed me to an article by another friend of ours: https://www.chinatalk.media/p/a-cancer-patients-tour-of-chin...

Here's the key quote:

> The tradeoff is pretty straightforward: the US system emphasizes uniform standards and upfront rigor, while China’s [investigator-initiated trial] model pushes decision-making closer to the doctor and the patient, making it easier to start trials quickly and iterate as data comes in

It's clear that they are prioritizing iteration over standardization - which is a good pathway to exploration but will yield results like this. In the end, we're all going to benefit from the new research coming out of China as they subject themselves to this high-variance policy.